AstraZeneca Makes Case For Independence With $23 Bil. Pipeline Potential
This article was originally published in The Pink Sheet Daily
The U.K. drug maker went on the offense against Pfizer’s hostile takeover attempt May 6, laying out to investors its long-term revenue guidance forecasting $45 billion in revenues by 2023. Growth will be driven by a pipeline with $23 billion in peak sales potential.